Primary plasma cell leukemia in the era of novel agents for myeloma – a multicenter retrospective analysis of outcome

•One-fifth of the patients died in the first 2 months after diagnosis.•The overall survival of those who survived the first 3 months was 22.5 months.•There was a survival advantage for those who received IMiD and for those who underwent hematopoietic cell transplantation.•In multivariate analysis, low performance status and increased uric acid were also associated with shorter overall survival.